Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and maintained a price target of $18.
October 04, 2023 | 10:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avadel Pharmaceuticals has received a reiterated 'Buy' rating from Needham analyst Ami Fadia, with a maintained price target of $18.
The reiterated 'Buy' rating and maintained price target by Needham analyst Ami Fadia indicates a positive outlook for Avadel Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100